In contrast, CD9 seems to be associated with a worse prognosis in ALL treated with intensive chemotherapy, as it was demonstrated in a cohort of 87 patients.30 These different results are probably explained by the association of CD9 in TEMs with different partners in ALL and AML. The gene discussed is CD9; the disease is acute myeloid leukemia.